Health News Releases

February 25, 2020 16:45

Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Applicati

February 25, 2020 14:37

Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN

Bioventus, a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System. EXOGEN uses low-intensity pulsed ultrasound (LIPUS

February 25, 2020 13:29

Arima Genomics Completes Series A Financing

Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has complete

February 25, 2020 13:07

Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong

Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary

February 20, 2020 17:50

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from m

February 20, 2020 10:55

Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced the

February 19, 2020 10:26

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to

February 17, 2020 13:35

Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutan

February 17, 2020 13:10

Octapharma Group Delivered Strong Growth in Both Sales and Operating Income In 2019

Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019. We achieved good growth in all three of our therap

February 17, 2020 09:41

Siemens Ltd. Seoul appoints Thomas Schmid as New Head of Digital Industries

A global powerhouse in electrical engineering and electronics leading the age of digitalization, Siemens Ltd. Seoul (SLS) announced the appointment of Mr. Thomas Schmid as Head of the company’s Digita

February 13, 2020 13:11

Sonion Announces Niels Svenningsen as New CEO & President

Sonion today announces the appointment of Niels Svenningsen as CEO & President of the Sonion Group. Niels Svenningsen was most recently President of Northern Europe in Schneider Electric and brings a

February 13, 2020 10:11

CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes

Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increase the risk of adverse cardiovascular events or hypoglyc

February 12, 2020 19:21

PCI Pharma Services Announces the Acquisition of Bellwyck Pharma Services to Expand Global Clinical Trial Services into Canada and Continental Europe

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered

February 12, 2020 17:48

SpeeDx Pty. Ltd. Raises Additional $15 million in Series B Funding

SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-base

February 11, 2020 09:58

OncoSec Announces Closing of the CGP/Sirtex Transaction

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the

February 10, 2020 22:00

Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020

Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive da

February 10, 2020 22:00

Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and d

February 10, 2020 12:57

OncoSec Announces that Shareholders Have Approved CGP/Sirtex Transaction

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, at its Special Meeting of Shareholde

February 10, 2020 11:40

OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the District

February 07, 2020 13:29

Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Congress this week, which takes place in The Hague, Th

February 06, 2020 17:51

Respimat® re-usable inhaler wins 2020 Pharmapack Eco-Design Award

Boehringer Ingelheim announced today that its Respimat® re-usable inhaler device is the winner of the 2020 Pharmapack Eco-Design Award. The Pharmapack Awards celebrate the latest innovations from pack

February 05, 2020 18:13

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that nine hematology abstracts are being presented at the 13th Annual Congress of the European Association for Hae

February 05, 2020 13:42

UNGC Network Korea and KoSIF launch “Business Integrity Society” to fight against corruption in collaboration with Siemens Integrity Initiative,

United Nations Global Compact (UNGC) Network Korea and Korea Sustainability Investing Forum (KoSIF) announced the launch of a new anti-corruption project called “Business Integrity Society (BIS)” unde

February 05, 2020 11:50

Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200203005855/en/ Underl

February 05, 2020 09:07

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy aimed at breaking the cycle of recurrent Clo

News by Region

News by Industry